Assertio Holdings Past Earnings Performance

Past criteria checks 0/6

Assertio Holdings's earnings have been declining at an average annual rate of -4.1%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been declining at an average rate of 3.9% per year.

Key information

-4.1%

Earnings growth rate

31.1%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	-3.9%
Return on equity	-247.6%
Net Margin	-234.4%
Last Earnings Update	31 Mar 2024

Recent past performance updates

Recent updates

Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

May 07

Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?

Apr 18

Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified

Mar 13

We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt

Apr 26

Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?

Mar 02

Revenue & Expenses Breakdown
Beta

How Assertio Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:ASRT Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 24	142	-333	71	4
31 Dec 23	152	-332	70	3
30 Sep 23	169	-186	66	2
30 Jun 23	168	98	61	1
31 Mar 23	162	97	55	0
31 Dec 22	156	110	48	0
30 Sep 22	139	26	35	0
30 Jun 22	130	25	41	0
31 Mar 22	121	3	43	0
31 Dec 21	111	-1	46	0
30 Sep 21	110	-30	69	0
30 Jun 21	119	-44	75	2
31 Mar 21	114	-65	90	3
31 Dec 20	108	-28	104	4
30 Sep 20	135	-196	106	10
30 Jun 20	156	-183	116	10
31 Mar 20	192	-162	113	9
31 Dec 19	230	-217	110	10
30 Sep 19	157	-49	111	7
30 Jun 19	180	-4	108	7
31 Mar 19	186	-11	116	8
31 Dec 18	256	37	120	8
30 Sep 18	364	28	143	7
30 Jun 18	381	-36	160	7
31 Mar 18	419	-42	179	10
31 Dec 17	381	-102	203	14
30 Sep 17	410	-114	203	22
30 Jun 17	425	-111	205	30
31 Mar 17	442	-95	206	32
31 Dec 16	456	-89	205	33
30 Sep 16	443	-75	194	30
30 Jun 16	437	-74	192	24
31 Mar 16	415	-85	197	22
31 Dec 15	343	-76	179	18
30 Sep 15	426	50	170	13
30 Jun 15	373	68	148	10
31 Mar 15	346	102	123	7
31 Dec 14	390	132	121	7
30 Sep 14	236	79	119	7
30 Jun 14	222	79	119	7
31 Mar 14	185	67	112	7
31 Dec 13	134	43	105	8
30 Sep 13	120	-2	102	9
30 Jun 13	116	-10	102	13

Quality Earnings: ASRT is currently unprofitable.

Growing Profit Margin: ASRT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ASRT is unprofitable, and losses have increased over the past 5 years at a rate of 4.1% per year.

Accelerating Growth: Unable to compare ASRT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASRT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).

Return on Equity

High ROE: ASRT has a negative Return on Equity (-247.57%), as it is currently unprofitable.

Assertio Holdings Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Assertio Holdings, Inc. to Report Q1, 2024 Results on May 06, 2024

Full year 2023 earnings: EPS misses analyst expectations

Assertio Holdings, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Assertio Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Assertio Holdings, Inc. Reiterates Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Assertio Holdings, Inc. to Report Q1, 2024 Results on May 06, 2024

Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?

Assertio Holdings, Inc., Annual General Meeting, May 23, 2024

Consensus revenue estimates fall by 27%

Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified

Full year 2023 earnings: EPS misses analyst expectations

Assertio Holdings, Inc. Provides Earnings Guidance for the Year 2024

Assertio Holdings, Inc. to Report Q4, 2023 Results on Mar 11, 2024

New major risk - Share price stability

Assertio Holdings, Inc. Announces the Resignation of Daniel A. Peisert as Member of the Board of Directors

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Assertio Holdings, Inc

Assertio Holdings, Inc. Announces Executive Changes

Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors

New minor risk - Market cap size

Assertio Holdings, Inc. Announces CFO Changes

New minor risk - Profitability

Consensus EPS estimates fall by 18%

Assertio Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023

President recently sold US$479k worth of stock

President notifies of intention to sell stock

New major risk - Shareholder dilution

Independent Director notifies of intention to sell stock

New minor risk - Share price stability

Assertio Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $25 million.

Consensus revenue estimates increase by 13%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Assertio Holdings, Inc. Withdraws Earnings Guidance for the Year 2023

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Assertio Holdings, Inc. Appoints Jeffrey Vacirca to Its Board of Directors

Assertio Holdings, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Independent Director recently sold US$652k worth of stock

President exercised options and sold US$2.9m worth of stock

Consensus EPS estimates fall by 30%, revenue upgraded

Assertio Holdings, Inc. Raises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 17%

We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued

Price target increased by 9.6% to US$7.88

Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?

Investor sentiment improves as stock rises 18%

Consensus EPS estimates increase by 164%

President exercised options and sold US$257k worth of stock

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 11%

Investor sentiment deteriorated over the past week

Insufficient new directors

Assertio Holdings, Inc. Revises Net Product Sales Guidance for the Year 2022

Assertio Holdings, Inc. Revises Earnings Guidance for the Full Year 2022

Assertio Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Assertio Holdings Looks Good To Rebound After Recent Price Plunge

Assertio Holdings: Substantial Upside

Assertio Holdings, Inc. Raises Earnings Guidance for the Year 2022

Assertio Therapeutics Q2 2022 Earnings Preview

Assertio Holdings, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Assertio Holdings: Management Still Swimming Against The Tide

Assertio's Phenomenal Turnaround

Assertio Holdings, Inc. Re-Affirms Sales Guidance for the Full Year of 2022

Levi & Korsinsky, LLP Announces Propose Settlement Against Assertio Therapeutics, Inc. Securities Litigation

Assertio Holdings, Inc. to Report Q1, 2022 Results on May 09, 2022

Assertio Holdings: Recent Breakout To Lead To Sustained Gains

Assertio Holdings, Inc., Annual General Meeting, May 04, 2022

Assertio Holdings, Inc. to Report Fiscal Year 2021 Results on Mar 09, 2022

Assertio's Digital Strategy Looks To Be Paying Off

Revenue & Expenses Breakdown
Beta